Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment

Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step in its mission to redefine first-line treatment ... Read More